Although anti-sclerostin monoclonal antibody is expected for a novel therapeutic drug for the treatment of osteoporosis [6], there are no effective drugs for the treatment of both sarcopenia and osteoporosis at the present time. This evidence concerns the gene SOST and sarcopenia.